{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-019803","form_type":"8-K","ticker":"NRXP","cik":"0001719406","company_name":"NRX Pharmaceuticals, Inc.","filed_at":"2025-06-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.461208+00:00","generated_at":"2026-05-19T17:19:11.167004+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"NRx Pharma files ANDA for preservative-free IV ketamine; market at $750M","bullets":["Filed ANDA for NRX-100 (preservative-free IV ketamine) with FDA; seeks priority review due to drug shortage.","Ketamine market currently $750M, projected to reach $3.35B globally by 2034.","Plans citizen petition to remove benzethonium chloride from all IV ketamine products.","Complements ongoing NDA for suicidal depression; PDUFA target late 2025; FDA waived $4.3M fee.","Patent protection sought through 2045; Fast Track designation previously granted."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-019803","json":"https://secwatch.observer/filing/0001437749-25-019803.json","markdown":"https://secwatch.observer/filing/0001437749-25-019803.md","text":"https://secwatch.observer/filing/0001437749-25-019803.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719406/000143774925019803/0001437749-25-019803-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719406/000143774925019803/nrxp20250607_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T17:19:11.167004+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}